Abstract
Purpose
To investigate the success (glaucoma control) of latanoprost therapy of primary congenital glaucoma (PCG) and factors affecting the long-term outcome.
Methods
Patients with PCG treated with latanoprost were re-examined. At study visit and from clinical charts, we evaluated: intraocular pressure, length of glaucoma control with latanoprost, need of further medication or glaucoma surgery, systemic and topical side effects. Multivariate analysis was used to test factors related to the final outcome of the treatment.
Results
Eighty-one eyes of 44 patients with PCG, and 42 eyes of 29 patients with previous glaucoma surgery, had received latanoprost therapy. In the first group, a success (glaucoma control by latanoprost therapy) was found in 24 eyes (29.6%), whereas 57 eyes (70.4%) had received surgery (45 eyes (55.6%) in the first year); among the eyes with previous surgery, a success was found in 12 eyes (28.6%), 13 eyes (31%) required an additional therapy, and 17 eyes (40.5%) had received further glaucoma surgery. No patient discontinued the treatment because of side effects. Factors related to the failure of the latanoprost treatment were: the high score of severity of glaucoma (P=0.014) and low age at PCG presentation (P=0.042).
Conclusions
Long-term treatment with latanoprost is effective in about 30% of the eyes; factors related to failure were severe glaucomatous alterations, and young age at PCG presentation.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
European glaucoma society. Terminology and Guidelines for Glaucoma 3rd edn. Editrice Dogma: Savona, Italy, 2008 pp 93–94.
Dureau P . Congenital glaucoma and trabeculodysgenesis. Clinical and genetic aspects. J Fr Ophtalmol 2006; 29: 198–215.
Passo MS, Palmer EA, Van Buskirk EM . Plasma timolol in glaucoma patients. Ophthalmology 1984; 91: 1361–1363.
Levy Y, Zadok D . Systemic side effects of ophthalmic drops. Clin Pediatr 2004; 43: 99–101.
Bucolo C, Salomone S, Drago F, Reibaldi M, Longo A, Uva MG . Pharmacological management of ocular hypertension: current approaches and future prospective. Curr Opin Pharmacol 2013; 13: 50–55.
European glaucoma society. Terminology and Guidelines for Glaucoma 3rd edn. Editrice Dogma: Savona, Italy, 2008 pp 136–138.
Yang CB, Freedman SF, Myers JS, Buckley EG, Herndon LW, Allingham RR . Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome. Am J Ophthalmol 1998; 126: 600–602.
Enyedi LB, Freedman SF, Buckley EG . The effectiveness of latanoprost for the treatment of pediatric glaucoma. J AAPOS 1999; 3: 33–39.
Enyedi LB, Freedman SF . Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol 2002; 47: 129–132.
Black AC, Jones S, Yanovitch TL, Enyedi LB, Stinnett SS, Freedman SF . Latanoprost in pediatric glaucoma—pediatric exposure over a decade. J AAPOS 2009; 13: 558–562.
Maeda-Chubachi T, Chi-Burris K, Simons BD, Freedman SF, Khaw PT, Wirostko B et al. A6111137 Study Group. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study. Ophthalmology 2011; 118: 2014–2021.
Al-Hazmi A, Awad A, Zwaan J, Al-Mesfer SA, Al-Jadaan I, Al-Mohammed A . Correlation between surgical success rate and severity of congenital glaucoma. Br J Ophthalmol 2005; 89: 449–453.
Maeda-Chubachi T, Chi-Burris K, Simons B, Brémond-Gignac D, Freedman S, Khaw PT et alA6111137 Study Group. Impact of age, diagnosis, and history of glaucoma surgery on outcomes in pediatric patients treated with latanoprost. J Glaucoma 2013; 22: 614–619.
Dureau P, Dollfus H, Cassegrain C, Dufier JL . Long-term results of trabeculectomy for congenital glaucoma. J Pediatr Ophthalmol Strabismus 1998; 35: 198–202.
Uva MG, Longo A, Cannemi V, Reibaldi A . Efficacy and Safety of Latanoprost in Congenital Glaucoma. Invest Ophthalmol Vis Sci 2003; 44, E-Abstract 2163.
Le Rebeller MJ, Lagoutte F . Spontaneous resolution of a case of congenital glaucoma. Bull Soc Ophtalmol Fr 1975; 75: 555–559.
Lockie P, Elder J . Spontaneous resolution of primary congenital glaucoma. Aust N Z J Ophthalmol 1989; 17: 75–77.
Nagao K, Noël LP, Noël ME, Walton DS . The spontaneous resolution of primary congenital glaucoma. J Pediatr Ophthalmol Strabismus 2009; 46: 139–143.
Alm A, Grierson I, Shields MB. . Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008; 53 (suppl 1): S93–105.
Albert DM, Gangnon RE, Grossniklaus HE, Green WR, Darjatmoko S, Kulkarni AD . A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides. Arch Ophthalmol 2008; 126: 626–631.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Uva, M., Avitabile, T., Reibaldi, M. et al. Long-term efficacy of latanoprost in primary congenital glaucoma. Eye 28, 53–57 (2014). https://doi.org/10.1038/eye.2013.232
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2013.232
Keywords
This article is cited by
-
Pediatric Glaucoma: Pharmacotherapeutic Options
Pediatric Drugs (2016)
-
Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Advances in Therapy (2016)
-
Evolving Perspectives on Congenital Glaucoma
Current Ophthalmology Reports (2015)
-
Latanoprost
Reactions Weekly (2014)
